REFERENCES
- Tietjen GE, Gottwald L, Al-Qasmi MM, Gunda P, Khuder SA. Migraine is associated with livedo reticularis: a prospective study. Headache. 2002;42:263–7.
- Gibbs MB. Livedo reticularis: an update. J Am Acad Dermatol. 2005;52:1009–19.
- Timberlake WH, Vance MA. Four-year treatment of patients with Parkinsonism using amantadine alone with levadopa. Am Neurol Assoc. 1978;3:119–28.
- Hayes BB, Cook-Norris RH, Miller JL, Rodriguez A, Zic JA. Amantadine-induced livedo reticularis: a report of two cases. J Drugs Dermatol. 2006;5:288–9.
- Singer C. Rimantadine in PD patients experiencing peripheral adverse effects from amantadine: report of a case series. Movement Disord. 2005;20:873–7.
- Duval A, Pouchot J. Livedo: De la physiopathologie au diagnostic. La Revue De Medecine Interne. 2008;29:380–92.
- Sladden MJ, Nicolaou N, Johnston GA, Hutchinson PE. Livedo reticularis induced by amatadine. Brit J Dermatol. 2003;149:656–8.
- Nishikawa N. Plasma amantadine concentrations in patients with Parkinson's disease. Parkinsonism Rel Disord. 2009;15:351–3.
- Loffler H, Habermann B, Effendy I. Amantadin-induced livedo reticularis. Hautarzt. 1998;49:224–7.
- Dean SM. Livedo reticularis and related disorders. Curr Trea Opt Cardiovasc Med. 2011;13:179–9.